Fulcrum Therapeutics (FULC) EBIT (2020 - 2025)
Historic EBIT for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to -$21.9 million.
- Fulcrum Therapeutics' EBIT rose 1300.64% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.2 million, marking a year-over-year decrease of 18308.6%. This contributed to the annual value of -$21.9 million for FY2024, which is 8021.31% up from last year.
- Fulcrum Therapeutics' EBIT amounted to -$21.9 million in Q3 2025, which was up 1300.64% from -$19.8 million recorded in Q2 2025.
- Fulcrum Therapeutics' EBIT's 5-year high stood at $52.5 million during Q2 2024, with a 5-year trough of -$34.2 million in Q2 2022.
- Moreover, its 5-year median value for EBIT was -$24.7 million (2022), whereas its average is -$20.4 million.
- In the last 5 years, Fulcrum Therapeutics' EBIT surged by 29233.48% in 2024 and then tumbled by 13774.86% in 2025.
- Quarter analysis of 5 years shows Fulcrum Therapeutics' EBIT stood at -$23.6 million in 2021, then fell by 18.74% to -$28.0 million in 2022, then decreased by 0.07% to -$28.0 million in 2023, then surged by 30.59% to -$19.4 million in 2024, then dropped by 12.5% to -$21.9 million in 2025.
- Its EBIT was -$21.9 million in Q3 2025, compared to -$19.8 million in Q2 2025 and -$19.4 million in Q4 2024.